Future prospects in the treatment of erectile dysfunction: Focus on avanafil

Drug Design, Development and Therapy

Volumn 5, Issue , 2011, Pages 435-443

  Alwaal, Amjad ^a   Al Mannie, Raed ^a   Carrier, Serge ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

PDE5; Pharmacokinetics; Sexual performance

Indexed keywords

2 (4 AMINOPHENYL) 1,2 DIHYDRO 1 OXO 7 (2 PYRIDINYLMETHOXY) 4 (3,4,5 TRIMETHOXYPHENYL) 3 ISOQUINOLINECARBOXYLIC ACID METHYL ESTER; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; APOMORPHINE; AVANAFIL; BREMELANOTIDE; FR 226807; GISADENAFIL; GLUTAMIC ACID; HEXARELIN; JNJ 10280205; JNJ 10287069; KF 31327; M VIX; MIRODENAFIL; PAPAVERINE; PHENTOLAMINE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTAGLANDIN E1; SEROTONIN 2C AGONIST; SILDENAFIL; SLX 2101; TADALAFIL; TRAZODONE; UDENAFIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARDENAFIL; VASOACTIVE INTESTINAL POLYPEPTIDE; YM 348;

BACKACHE; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DIZZINESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FATIGUE; FLUSHING; GENE THERAPY; HEADACHE; HEARING LOSS; HEMATOMA; HUMAN; INTERMETHOD COMPARISON; MAXIMUM PLASMA CONCENTRATION; MEDICAL INSTRUMENTATION; MONOTHERAPY; MUSCLE CRAMP; MYALGIA; NAUSEA; NONHUMAN; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PAIN; PENILE FIBROSIS; PENIS DISEASE; PETECHIA; PEYRONIE DISEASE; PRIAPISM; REGENERATIVE MEDICINE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SKIN NECROSIS; SURVIVAL RATE; SURVIVAL TIME; SYNCOPE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT FAILURE; URETHRAL BLEEDING; UROGENITAL TRACT DISEASE; VACUUM ERECTION DEVICE; VISUAL IMPAIRMENT;

CLINICAL TRIALS AS TOPIC; ERECTILE DYSFUNCTION; HUMANS; MALE; PHOSPHODIESTERASE 5 INHIBITORS; PYRIMIDINES;

EID: 84859112058     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S15852     Document Type: Review

References (79)

1. Lue TF, Giuliano F, Montorsi F, et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med. 2004;1(1):6-23.
2. Wagner G, Fugl-Meyer KS, Fugl-Meyer AR. Impact of erectile dysfunction on quality of life: patient and partner perspectives. Int J Impot Res. Oct 2000;12 Suppl 4:S144-S146.
3. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54-61.
4. Dean RC, Lue TF. Physiology of penile erection and pathophysiology of erectile dysfunction. Urol Clin North Am. Nov 2005;32(4):379-395, v.
5. Lizza EF, Rosen RC. Definition and classification of erectile dysfunction: report of the Nomenclature Committee of the International Society of Impotence Research. Int J Impot Res. 1999;11(3):141-143.
6. Hanash KA. Comparative results of goal oriented therapy for erectile dysfunction. J Urol. 1997;157(6):2135-2138.
7. Montague DK, Jarow JP, Broderick GA, et al. Chapter 1: The management of erectile dysfunction: an AUA update. J Urol. 2005;174(1):230-239.
8. Gupta M, Kovar A, Meibohm B. The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. J Clin Pharmacol. 2005;45(9):987-1003.
9. Nichols DJ, Muirhead GJ, Harness JA. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol. 2002;53: 5S-12S.
10. Gingell C, Sultana SR, Wulff MB, Gepi-Attee S. Duration of action of sildenafil citrate in men with erectile dysfunction. J Sex Med. 2004;1(2): 179-184.
11. Cheitlin MD, Hutter AM Jr, Brindis RG, et al. Use of sildenafil (Viagra) in patients with cardiovascular disease. Circulation. 1999;99(1): 168-177.
12. Boolell M, Allen MJ, Ballard SA, et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res. 1996;8(2):47-52.
13. Klotz T, Sachse R, Heidrich A, et al. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World J Urol. 2001;19(1):32-39.
14. Stark S, Sachse R, Liedl T, et al. Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. Eur Urol. 2001;40(2):181-188.
15. Rajagopalan P, Mazzu A, Xia C, Dawkins R, Sundaresan P. Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. J Clin Pharmacol. 2003;43(3):260-267.
16. Gresser U, Gleiter CH. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil-review of the literature. Eur J Med Res. 2002;7(10):435-446.
17. Eardley I, Cartledge J. Tadalafil (Cialis) for men with erectile dysfunction. Int J Clin Pract. 2002;56(4):300-304.
18. Brock G. Tadalafil: a new agent for erectile dysfunction. Can J Urol. 2003;10(Suppl 1):17-22.
19. Hellstrom WJG, Overstreet JW, Yu A, et al. Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones. J Urol. 2003;170(3):887-891.
20. Hatzimouratidis K, Hatzichristou DG. A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient? Drugs. 2005;65(12):1621-1650.
21. Vlachopoulos C, Ioakeimidis N, Rokkas K, Stefanadis C. Cardiovascular effects of phosphodiesterase type 5 inhibitors. J Sex Med. 2009;6(3): 658-674.
22. Kloner RA. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions. Am J Cardiol. 2005;96(12B):42M-46M.
23. Hatzimouratidis K, Hatzichristou DG. Looking to the future for erectile dysfunction therapies. Drugs. 2008;68(2):231-250.
24. Wespes E, Amar E, Hatzichristou D, et al. EAU guidelines on erectile dysfunction: an update. Eur Urol. 2006;49(5):806-815.
25. Hatzichristou D. Phosphodiesterase 5 inhibitors and nonarteritic anterior ischemic optic neuropathy (NAION): coincidence or causality? J Sex Med. 2005;2(6):751-758.
26. Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N Engl J Med. 1996;334(14):873-877.
27. Kaplan SA, Reis RB, Kohn IJ, Shabsigh R, Te AE. Combination therapy using oral alpha-blockers and intracavernosal injection in men with erectile dysfunction. Urology. 1998;52(5):739-743.
28. Bennett AH, Carpenter AJ, Barada JH. An improved vasoactive drug combination for a pharmacological erection program. J Urol. 1991; 146(6):1564-1565.
29. Moemen MN, Hamed HA, Kamel II, Shamloul RM, Ghanem HM. Clinical and sonographic assessment of the side effects of intracavernous injection of vasoactive substances. Int J Impot Res. 2004;16(2): 143-145.
30. Shokeir AA, Alserafi MA, Mutabagani H. Intracavernosal versus intraurethral alprostadil: a prospective randomized study. BJU Int. 1999;83(7):812-815.
31. Oakley N, Moore KT. Vacuum devices in erectile dysfunction: indications and efficacy. Br J Urol. 1998;82(5):673-681.
32. Minervini A, Ralph DJ, Pryor JP. Outcome of penile prosthesis implantation for treating erectile dysfunction: experience with 504 procedures. BJU Int. 2006;97(1):129-133.
33. Montague DK, Angermeier KW. Penile prosthesis implantation. Urol Clin North Am. 2001;28(2):355-361, x.
34. Paick J-S, Kim SW, Yang DY, et al. The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. J Sex Med. 2008;5(4):946-953.
35. Prince W, Campbell AS, Tong W, et al. SLx-2101, a new long-acting PDE5 inhibitor: preliminary safety, tolerability, PK and endothelial function effects in healthy subjects. J Sex Med. 2006;3(Suppl 1):29-30.
36. Paick JS, Ahn TY, Choi HK, et al. Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction. J Sex Med. 2008;5(11):2672-2680.
37. Hosogai N, Hamada K, Tomita M, et al. FR226807: a potent and selective phosphodiesterase type 5 inhibitor. Eur J Pharmacol. 2001;428(2): 295-302.
38. Takagi M, Mochida H, Noto T, et al. Pharmacological profile of T-1032, a novel specific phosphodiesterase type 5 inhibitor, in isolated rat aorta and rabbit corpus cavernosum. Eur J Pharmacol. 2001;411(1-2):161-168.
39. Hirose R, Okumura H, Yoshimatsu A, et al. KF31327, a new potent and selective inhibitor of cyclic nucleotide phosphodiesterase 5. Eur J Pharmacol. 2001;431(1):17-24.
40. Qiu Y, Bhattacharjee S, Kraft P, et al. JNJ-10280205 and JNJ-10287069: novel PDE5 inhibitors as clinical candidates for erectile dysfunction. Int J Impot Res. 2006;18:477-483.
41. Kalsi JS, Kell PD, Cellek S, Ralph DJ. NCX-911, a novel nitric oxide-releasing PDE5 inhibitor relaxes rabbit corpus cavernosum in the absence of endogenous nitric oxide. Int J Impot Res. 2004;16:195-200.
42. Wessells H, Gralnek D, Dorr R, Hruby VJ, Hadley ME, Levine N. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology. 2000;56(4):641-646.
43. Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994(1):96-102.
44. Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res. 2004;16:135-142.
45. Safarinejad MR, Hosseini SY. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. J Urol. 2008;179(3):1066-1071.
46. Goldstein I, Payton TR, Schechter PJ. A double-blind, placebocontrolled, efficacy and safety study of topical gel formulation of 1% alprostadil (Topiglan) for the in-office treatment of erectile dysfunction. Urology. 2001;57(2):301-305.
47. Shah PJ, Dinsmore W, Oakes RA, Hackett G. Injection therapy for the treatment of erectile dysfunction: a comparison between alprostadil and a combination of vasoactive intestinal polypeptide and phentolamine mesilate. Curr Med Res Opin. 2007;23(10):2577-2583.
48. Eardley I, Wright P, MacDonagh R, Hole J, Edwards A. An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction. BJU International. 2004;93(9):1271-1275.
49. Riley A, Main M, Morgan F. Inhalation device allows novel administration of apomorphine in men with erectile dysfunction-efficacy and safety findings. J Sex Med. 2010;7(4 Pt 1):1508-1517.
50. Brioni JD, Moreland RB, Cowart M, et al. Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats. Proc Natl Acad Sci U S A. 2004;101(17):6758-6763.
51. Song Y, Rajasekaran M. Effect of excitatory amino acid receptor agonists on penile erection after administration into the CA3 hippocampal region in the rat. Urology. 2004;64(6):1250-1254.
52. Andersson KE. Pharmacology of penile erection. Pharmacol Rev. 2001; 53(3):417-450.
53. Lance R, Albo M, Costabile RA, Steers WD. Oral trazodone as empirical therapy for erectile dysfunction: a retrospective review. Urology. 1995;46(1):117-120.
54. Bancila M, Vergé D, Rampin O, et al. 5-Hydroxytryptamine 2C receptors on spinal neurons controlling penile erection in the rat. Neuroscience. 1999;92(4):1523-1537.
55. Kimura Y, Hatanaka K, Naitou Y, et al. Pharmacological profile of YM348, a novel, potent and orally active 5-HT2C receptor agonist. Eur J Pharmacol. 2004;483(1):37-43.
56. Kalsi JS, Rees RW, Hobbs AJ, et al. BAY41-2272, a novel nitric oxide independent soluble guanylate cyclase activator, relaxes human and rabbit corpus cavernosum in vitro. J Urol. 2003;169(2):761-766.
57. Stasch JP, Becker EM, Alonso-Alija C, et al. NO-independent regulatory site on soluble guanylate cyclase. Nature. 2001;410:212-215.
58. Somlyo AP, Somlyo AV. Signal transduction by G-proteins, Rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. J Physiol. 2000;522(2):177-185.
59. Chitaley K, Wingard CJ, Clinton Webb R, et al. Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway. Nat Med. 2001;7:119-122.
60. Dai Y, Chitaley K, Webb RC, Lewis RW, Mills TM. Topical application of a Rho-kinase inhibitor in rats causes penile erection. Int J Impot Res. 2004;16:294-298.
61. Succu S, Mascia MS, Melis T, et al. Pro-VGF-derived peptides induce penile erection in male rats: involvement of paraventricular nitric oxide. Neuropharmacology. 2005;49(7):1017-1025.
62. Melis MR, Succu S, Spano MS, Deghenghi R, Argiolas A. EP 91073 prevents EP 80661-induced penile erection: new evidence for the existence of specific EP peptide receptors mediating penile erection. Neuropharmacology. 2001;41:254-262.
63. Melis MR, Succu S, Spano MS, et al. EP 60761 and EP 50885, two hexarelin analogues, induce penile erection in rats. Eur J Pharmacol. 2000;404(1-2):137-143.
64. Melis MR, Succu S, Argiolas A. Dopamine agonists increase nitric oxide production in the paraventricular nucleus of the hypothalamus: correlation with penile erection and yawning. Eur J Neurosci. 1996; 8(10):2056-2063.
65. Succu S, Sanna F, Melis T, Boi A, Argiolas A, Melis MR. Stimulation of dopamine receptors in the paraventricular nucleus of the hypothalamus of male rats induces penile erection and increases extra-cellular dopamine in the nucleus accumbens: involvement of central oxytocin. Neuropharmacology. 2007;52(3):1034-1043.
66. Melman A, Bar-Chama N, McCullough A, Davies K, Christ G. hMaxi-K gene transfer in males with erectile dysfunction: results of the first human trial. Hum Gene Ther. 2006;17(12):1165-1176.
67. Kim ED, Scardino PT, Hampel ORI, Mills NL, Wheeler TM, Nath RK. Interposition of sural nerve restores function of cavernous nerves resected during radical prostatectomy. J Urol. 1999;161(1): 188-192.
68. Kershen RT, Yoo JJ, Moreland RB, Krane RJ, Atala A. Reconstitution of human corpus cavernosum smooth muscle in vitro and in vivo. Tissue Eng. 2002;8(3):515-524.
69. Falke G, Yoo JJ, Kwon TG, Moreland R, Atala A. Formation of corporal tissue architecture in vivo using human cavernosal muscle and endothelial cells seeded on collagen matrices. Tissue Eng. 2003;9(5): 871-879.
70. Pilatz A, Schultheiss D, Gabouev AI, et al. Isolation of primary endothelial and stromal cell cultures of the corpus cavernosum penis for basic research and tissue engineering. Eur Urol. 2005;47(5):710-719.
71. Limin M, Johnsen N, Hellstrom WJG. Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction. Expert Opin Investig Drugs. 2010;19(11):1427-1437.
72. Peterson C, Swearingen D. Pharmacokinetics of avanafil, a new PDE5 inhibitor being developed for erectile dysfunction. J Sex Med. 2006;3(Suppl 3):253-254.
73. Lewis RW, Hellstrom W, Gittelman M. Rigiscan evaluation of TA-1790, a novel PDE5 inhibitor for the treatment of men with erectile dysfunction. J Urol. 2006;171(4 Suppl):316.
74. Jung J, Choi S, Cho SH, et al. Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single-and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers. Clin Ther. 2010;32(6):1178-1187.
75. Results announced for TA-1790 Phase II head-to-head study with Viagra. VIVUS, Inc, press releases March 4, 2004. Available from: http://www.prnewswire.com/news-releases/vivus-announces-resultsfor-ta-1790-in-phase-2-head-to-head-study-with-viagrar-58872542. html.
76. Nehra A, Swearingen D, Dietrich J, Peterson C. Haemodynamic effects of co-administration of avanafil and glyceryl trinitrate. Eur Urol. 2006;5(2):138.
77. Kaufman J, Dietrich J. Safety and efficacy of avanafil, a new PDE5 inhibitor for treating erectile dysfunction. 2006;5(2):138.
78. Goldstein I. BC, DiDonato K, et al. Investigating avanafil in the treatment of erectile dysfunction: results of a Phase III, multicenter, randomized, double-blind, placebo controlled clinical trial. AUA Late-Breaking Science Forum 2010, San Francisco, CA; 2010.
79. VIVUS Announces Positive Results From Avanafil Phase 3 Study in Diabetics Presented at the 47th EASD Annual Meeting. 13 September 2011. Available from: http://ir.vivus.com/releasedetail.cfm?ReleaseID=604819.